In our study, the incidences of treatment-related rash and maculopapular rash were low overall (3% and 7%, respectively), whereas the incidence of treatment-related acneiform dermatitis was greatest in the highest dose combination group evaluated (40%) but was within the range reported with MEK inhibitors in the literature [18]. This evidence concerns the gene MAP2K7 and Skin rash.